News

Nasdaq3y
VBL Therapeutics Resumes U.S. Enrollment In Phase 3 Trial On Ovarian Cancer - Nasdaq
VBL has sufficient FDA-cleared batches and will resume patient recruitment in the OVAL trial in the United States. The OVAL trial, which evaluates VB-111 in ovarian cancer, ...
Yahoo Finance2y
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash - Yahoo Finance
MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced ...
Business Insider8y
VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM - Markets Insider
TEL AVIV, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the Independent Data Safety Monitoring ...
Business Insider8y
VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating OfficerIndustry leader with extensive oncology experience joins company ... - Markets Insider
TEL AVIV, Israel, June 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr. Epperly is an ...
Yahoo Finance2y
VBL Therapeutics Announces Workforce Reduction - Yahoo Finance
TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases ...
FierceBiotech2y
After a tough year, VBL merges with Notable Labs - Fierce Biotech
After a rocky 2022 for VBL Therapeutics, the biotech is merging with Notable Labs, a cancer-focused platform company that just pulled in $10.3 million from investors. The merger, which is set to ...